Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Biogen/Eisai Sets Primary Target in Aduhelm Confirmatory Study
January 31, 2022
- LEO Pharma Files Tralokinumab for Atopic Dermatitis in Japan
January 31, 2022
- Fujifilm to Buy Atara’s Cell Therapy Manufacturing Facility in US
January 28, 2022
- Otsuka Partners with VR Solution Firm to Offer Social Skills Training for Mental Health
January 28, 2022
- Otsuka Slashes Full Year Profits for 2021
January 28, 2022
- Jardiance’s New Indication Targets Around Half of Chronic Heart Failure Patients: Professor
January 28, 2022
- Yakult Honsha to Launch Velcade Generic in March
January 27, 2022
- Flatiron Health Joins Hands with National Cancer Center to Start Up Japan Biz
January 27, 2022
- Seikagaku Launches New Outpost in Canada
January 27, 2022
- Nippon Shinyaku Sets Up New Sales Firm in Tianjin to Expand Chinese Business
January 27, 2022
- Astellas to Revamp Japan Marketing Organization, Scrap Sales Offices as Biz Environment Evolves
January 26, 2022
- Nippon Shinyaku Snags US Commercial Rights to Capricor’s DMD Cell Therapy
January 26, 2022
- MSD Japan Set to Supply 1.6 Million Courses of Lagevrio by September: President
January 26, 2022
- Opdivo Combo Approved in Taiwan for 1st Line Non-Squamous NSCLC
January 26, 2022
- Abraxane Supply Secured until around July: Taiho
January 26, 2022
- Astellas Aims to Propel Digital Transformation to Become Value-Driven Innovator
January 25, 2022
- Aculys Pharma Gets APAC Rights to Neurelis’ Epilepsy Nasal Spray
January 25, 2022
- Novartis Downsizing Tokyo Head Office to Cut Costs and Support Diverse Work Styles
January 24, 2022
- Daiichi Sankyo to End Vaccine Collaboration with Kitasato Pharma
January 24, 2022
- JCR’s MPS IIIA Drug Gets Orphan Tag in Europe
January 24, 2022
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…